Pamplona (Spain), November 19th, 2020.The European consortium held its annual meeting to assess the difficulties and successes of this first year coinciding with the global pandemic.
On November 19th and 20th, the BRAVƎ cardiac regeneration project held its first annual meeting organized by the Clínica Universidad de Navarra. The conference brought together representatives of the 14 European institutions that make up the consortium in a virtual format. During two days, they analyzed the difficulties and progress achieved in this complicated first year of the project starring the pandemic caused by Covid-19.
“The biggest challenge this year has been to ensure that all partners could develop our research at the same time and establish coordinated ways of working to advance the project. With the emergence of Covid-19, the risk of stopping the project arose since the regulation in each laboratory and each country is different. However, thanks to everyone’s efforts, we have managed to work in a coordinated way and progress in the development of BRAVƎ,” says Dr Felipe Prósper, director of the Cell Therapy Area at Clínica Universidad de Navarra and the coordinator of the project.
Once the partners overcome this challenge, the consortium agreed to continue advancing in the following phases of the project to reach the following milestones in the next year: from a new bioreactor to some large scale bioengineered heart tissues.
Here you can see the first-person testimony of some of our partners, through a short video telling their difficulties, successes and challenges of this first year.
Caption: Virtual meeting screenshot
